We are open as normal during COVID-19 pandemic. Order online, same day shipping out from North Carolina, USA

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 530022

CAS#: 84210-26-4

Description: NZ-419, also known as HD003, is an antioxidant potentially for the treatment of renal failure.

Price and Availability

Size Price Shipping out time Quantity
Inquire bulk and customized quantity

Pricing updated 2020-09-20. Prices are subject to change without notice.

NZ-419 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to to inquire quote.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 530022
Name: NZ-419
CAS#: 84210-26-4
Chemical Formula: C4H6N2O2
Exact Mass: 114.04
Molecular Weight: 114.1
Elemental Analysis: C, 42.11; H, 5.30; N, 24.55; O, 28.04

Synonym: NZ-419; HD-003; NZ 419; HD 003; NZ419; HD003

IUPAC/Chemical Name: 1-methylimidazolidine-2,4-dione


InChi Code: InChI=1S/C4H6N2O2/c1-6-2-3(7)5-4(6)8/h2H2,1H3,(H,5,7,8)


Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:


1: Ienaga K, Sohn M, Naiki M, Jaffa AA. Creatinine metabolite, HMH (5-hydroxy-1-methylhydantoin; NZ-419), modulates bradykinin-induced changes in vascular smooth muscle cells. J Recept Signal Transduct Res. 2014 Jun;34(3):195-200. doi: 10.3109/10799893.2013.876039. PubMed PMID: 24641698.

2: Ienaga K, Park CH, Yokozawa T. Protective effect of an intrinsic antioxidant, HMH (5-hydroxy-1-methylhydantoin; NZ-419), against cellular damage of kidney tubules. Exp Toxicol Pathol. 2013 Jul;65(5):559-66. doi: 10.1016/j.etp.2012.05.001. PubMed PMID: 22749566.

3: Ienaga K, Yokozawa T. Creatinine and HMH (5-hydroxy-1-methylhydantoin, NZ-419) as intrinsic hydroxyl radical scavengers. Drug Discov Ther. 2011 Aug;5(4):162-75. PubMed PMID: 22466296.

4: Hasegawa G, Nakano K, Ienaga K. Serum accumulation of a creatinine oxidative metabolite (NZ-419: 5-hydroxy-1- methylhydatoin) as an intrinsic antioxidant in diabetic patients with or without chronic kidney disease. Clin Nephrol. 2011 Oct;76(4):284-9. PubMed PMID: 21955863.

5: Ienaga K, Yokozawa T. Treatment with NZ-419 (5-Hydroxy-1-methylimidazoline-2,4-dione), a novel intrinsic antioxidant, against the progression of chronic kidney disease at stages 3 and 4 in rats. Biol Pharm Bull. 2010;33(5):809-15. PubMed PMID: 20460759.

6: Ienaga K, Mikami H, Yokozawa T. First indications demonstrating the preventive effects of NZ-419, a novel intrinsic antioxidant, on the initiation and/or progression of chronic renal failure in rats. Biol Pharm Bull. 2009 Jul;32(7):1204-8. PubMed PMID: 19571386.

7: Gao L, Yang S, Liu J, Liu L. [Preventive effects of 5-hydroxy-1-methylhydantoin on paraquat-induced nephrotoxicity in rat]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2015 Apr;27(4):246-9. doi: 10.3760/cma.j.issn.2095-4352.2015.04.004. Chinese. PubMed PMID: 25891451.

8: Ienaga K, Nakamura K, Naka F, Goto T. The metabolism of 1-methylhydantoin via 5-hydroxy-1-methylhydantoin in mammals. Biochim Biophys Acta. 1988 Dec 15;967(3):441-3. PubMed PMID: 3196760.

9: Nakamura K, Ienaga K. Creatol (5-hydroxycreatinine), a new toxin candidate in uremic patients. Experientia. 1990 May 15;46(5):470-2. PubMed PMID: 2347396.